Last reviewed · How we verify
aprotonin; epsilon aminocaproic acid
This combination inhibits fibrinolysis by blocking plasmin-mediated clot breakdown, thereby reducing bleeding during and after surgery.
This combination inhibits fibrinolysis by blocking plasmin-mediated clot breakdown, thereby reducing bleeding during and after surgery. Used for Reduction of perioperative blood loss in cardiac surgery, Reduction of transfusion requirements in major surgical procedures.
At a glance
| Generic name | aprotonin; epsilon aminocaproic acid |
|---|---|
| Sponsor | University of Rochester |
| Drug class | Antifibrinolytic agent |
| Target | Plasmin, kallikrein, plasminogen activators |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Surgery |
| Phase | FDA-approved |
Mechanism of action
Aprotinin is a serine protease inhibitor that directly inhibits plasmin and kallikrein, while epsilon aminocaproic acid is a lysine analog that competitively inhibits plasminogen activation. Together, they work synergistically to prevent excessive fibrin degradation and reduce perioperative blood loss in surgical patients.
Approved indications
- Reduction of perioperative blood loss in cardiac surgery
- Reduction of transfusion requirements in major surgical procedures
Common side effects
- Thrombosis
- Myocardial infarction
- Stroke
- Renal dysfunction
- Hypersensitivity reactions
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- aprotonin; epsilon aminocaproic acid CI brief — competitive landscape report
- aprotonin; epsilon aminocaproic acid updates RSS · CI watch RSS
- University of Rochester portfolio CI